Investors Press Releases Feb 25 2026 Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA Read More Jan 20 2026 Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab Read More Jan 16 2026 Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares Read More btn News View All Events & Presentations Dec 16 2025 at 8:30 AM EST Dec 16 2025 at 8:30 AM EST Annual General Meeting 2025 Read More Dec 12 2024 at 8:30 AM EST Dec 12 2024 at 8:30 AM EST Annual General Meeting 2024 Read More Dec 14 2023 at 8:30 AM EST Dec 14 2023 at 8:30 AM EST Annual General Meeting 2023 Read More btn Events View All Interim Reports Interim Results for the Six Months Ended 30 June 2025 721.5 KB bth Interim Reports View All Annual Reports 20 F - Annual Report for the year ended 31 December 2024 1.4 MB btn ARs View All Annual General Meeting 2025 AGM Results 60.5 KB btn AGM View All Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Stock Chart
Feb 25 2026 Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA Read More
Jan 20 2026 Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab Read More
Jan 16 2026 Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares Read More